查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1837190

獸醫分子診斷市場按產品、技術、動物類型、疾病類型和最終用戶分類－2025-2032年全球預測

Veterinary Molecular Diagnostic Market by Product, Technology, Animal Type, Disease Type, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，獸醫分子診斷市場規模將成長 13.0176 億美元，複合年成長率為 9.44%。

關鍵市場統計數據
基準年 2024 6.324億美元
預計年份：2025年 6.9227億美元
預測年份 2032 13.176億美元
複合年成長率 (%) 9.44%

在獸醫分子診斷領域，面對快速的技術進步和不斷變化的業務挑戰，為決策者提供必要的背景資訊。

獸醫分子診斷領域正處於快速技術創新與獸醫醫療保健產業對準確、及時檢測日益成長的需求交匯點。聚合酵素鏈鎖反應)、數位和等溫擴增技術、微陣列平台以及高通量定序的最新進展，正在拓展檢測傳染性病原體、鑑定遺傳疾病以及支持獸醫臨床腫瘤治療的可能性。同時，從學術機構和研究中心到診斷實驗室和臨床動物醫院，終端使用者群體不斷擴大，這正在建立一個更複雜的生態系統，在這個系統中，診斷必須具備穩健性、成本效益，並與臨床工作流程無縫銜接。

隨著診斷能力的不斷發展，相關人員面臨著動態的監管環境、複雜的供應鏈以及跨部門合作。曾經透過成熟經銷商穩定採購的儀器和耗材，如今受到全球貿易動態和供應商整合的影響；同時，用於將原始數據轉化為可執行臨床決策的軟體和解讀服務也變得日益重要。本導言強調了技術選擇、營運能力和市場服務之間策略協調的必要性，為後續分析組裝。透過將讀者置於這一動態環境中，接下來的敘述將揭示變革性趨勢、監管壓力、細分市場主導的機遇，並提出應對近期挑戰和加速在不同動物物種和醫療保健環境中推廣應用的建議措施。

總的來說，本節為決策者和研究人員評估風險、確定投資優先順序以及製定干涉措施以利用分子診斷改善動物健康並管理營運複雜性奠定了基礎。

檢驗將徹底改變動物分子診斷技術開發、檢驗和交付方式的關鍵技術、監管和營運變革。

在技​​術融合、臨床需求變化以及供應鏈和報銷模式面臨的機構壓力等因素的共同推動下，獸醫分子診斷領域正經歷一場變革。次世代定序儀正從小眾研究應用轉向病原體發現和抗菌藥物抗藥性分析等更常規的應用，而即時PCR和數位PCR仍然是標靶、高靈敏度檢測的主力。同時，等溫擴增技術和可攜式平台正推動水產養殖、畜牧業和野生動物監測領域的照護現場和現場診斷，從而支持更快的疫情應對和畜群層面的決策。這些變革得益於生物資訊學和雲端基礎解讀技術的進步，縮短了周轉時間，並使複雜分析的普及化。

試劑供應商和儀器提供者的整合、對診斷驗證和資料完整性日益嚴格的監管審查，以及終端用戶對包含檢測、儀器和解讀服務的捆綁式解決方案的需求不斷成長，都在重塑市場動態。此外，多檢體物檢測組合的日益複雜以及對跨平台相容性的需求，也推動了對開放式架構儀器和檢驗耗材的重視。因此，檢測開發商、平台提供者和研發機構之間的夥伴關係正成為加快產品上市速度和確保臨床效用的策略要務。

簡而言之，該行業正從孤立的技術部署轉向以服務為導向的整合模式，強調數據驅動的診斷、營運彈性以及可擴展的工作流程。相關人員，將在日益複雜、以結果為導向的動物保健市場中獲得競爭優勢。

分析2025年美國關稅對獸醫分子診斷供應鏈的多方面營運與採購影響

到2025年，美國關稅政策的累積變化將對獸醫分子診斷供應鏈、籌資策略和成本結構產生多方面的影響。進口設備和某些試劑關稅的提高正在加劇實驗室採購預算的壓力，並影響高容量設備和一次性耗材的採購決策。因此，一些實驗室和獸醫網路正在加快在地化策略的實施，並尋求國內經銷商和區域製造合作夥伴，以降低貿易摩擦帶來的風險並避免庫存波動。

這些貿易措施也促使買家重新評估PCR儀、定序儀和輔助自動化設備的總擁有成本，考慮到前置作業時間延長、維護合約需要重新協商以及備件成本增加等因素。對於試劑密集型工作流程而言，原料和特殊酵素的關稅促使企業更加重視供應多元化、庫存避險以及與能夠確保供應連續性的供應商簽訂更長的合約期限。同時，對跨境實體運輸依賴性較低的軟體和解讀服務已成為一種低關稅途徑，可為診斷服務增值並抵消硬體相關的成本壓力。

監管和採購團隊已採取應對措施，包括重新談判供應商合約、尋求與區域製造商建立策略夥伴關係關係，以及優先選擇可相容多種有效耗材的開放平台儀器，以降低單一供應商風險。同時，實驗室也在增加對工作流程效率和多重檢測的投資，以降低每次檢測的試劑消費量。總而言之，這些因應措施正在重塑採購模式，促進更具協作性的供應商關係，並加速採用能夠在貿易保護主義盛行的環境下平衡成本、性能和供應鏈安全的彈性採購慣例。

解鎖跨產品、技術、動物類型、疾病和最終用戶環境的詳細細分，以指導有針對性的診斷策略和開發。

對市場區隔的深入理解揭示了需求的來源、技術選擇如何與物種和疾病優先事項相交，以及哪些終端使用者環境將推動技術的持續應用。產品包括耗材和試劑、儀器以及軟體和服務。耗材和試劑可以理解為酵素製劑、檢測試劑套件以及對檢測靈敏度和特異性至關重要的探針和引子；而儀器則根據不同的通量和應用需求進行分類，從PCR儀到定序儀。軟體和服務日益成為連接各方的紐帶，實現數據解讀、工作流程編配和遠距離診斷。

從技術角度來看，傳統PCR、數位PCR、等溫擴增、微陣列、次世代定序和即時PCR各有其獨特的價值提案。次世代定序儀本身涵蓋了Illumina、Ion Torrent和Oxford Nanopore等多種技術，每種技術在讀長、通量和現場應用性方面各有優劣。這些技術選擇與動物類型密切相關：水產養殖中魚貝類的檢測需要穩健可靠且通常可現場應用的檢測方法；禽類檢測優先考慮快速牛檢測以保護畜群健康；伴侶動物診斷，特別是犬貓的診斷，側重於遺傳疾病篩檢和腫瘤檢測；則是研究動物

此外，野生動物檢測需要以廣泛發現和保護病原體為重點的基因分析。疾病細分進一步細化了檢驗和開發重點：遺傳性疾病需要高保真度基因型鑒定檢測，感染疾病需要靈敏快速地檢測細菌、真菌、寄生蟲和病毒等病原體，而腫瘤則需要能夠分析腫瘤相關變異的檢測方法。最後，最終用戶——學術機構、診斷中心、參考實驗室、研究機構以及獸醫診所和臨床診所——在通量、監管要求和採用複雜工作流程的意願方面各不相同。學術研究機構通常會試驗創新技術和生物資訊學方法，參考實驗室優先考慮具有嚴格品質控制的標準化高通量檢測，而臨床獸醫診所則尋求能夠快速提供可解釋結果並指導患者照護的整合解決方案。總而言之，這些細分為產品開發、檢驗策略和市場推廣優先順序提供了藍圖，使技術能力與每個使用者群體的營運需求相匹配。

繪製美洲、歐洲、中東和非洲以及亞太地區的需求促進因素、基礎設施成熟度和監管差異圖，為部署策略提供資訊。

區域動態在塑造獸醫分子診斷的需求、監管方式和部署模式方面發揮著至關重要的作用。在美洲，成熟的獸醫服務市場、強大的研究基礎設施以及先進的畜牧和伴侶動物護理生態系統，推動了對高通量平台、專用試劑和整合軟體解決方案的需求，這些解決方案既支持臨床決策，也支持流行病學監測。此外，該地區龐大的私人獸醫診所和參考文獻實驗室基礎，也有利於早期採用針對伴侶動物和畜牧物種的新型檢測方法和伴侶診斷技術。

在歐洲、中東和非洲，不同的法規環境和實驗室能力水準導致了不同的應用模式。西歐和北歐市場傾向於採用驗證標準更為嚴格的複雜技術，而中東和非洲部分地區則優先考慮經濟高效、可現場使用的診斷方法，以管控通用動物和感染疾病的風險。能力建構和官民合作關係，以及旨在加強實驗室網路和數據共用框架的合作舉措，正在加速多個次區域分子診斷技術的部署。

亞太地區獸醫服務、大規模水產養殖業和密集畜牧生產體系的快速發展，推動了可擴展診斷和監測工具的需求。該地區各國正投資於定序和多重檢測能力，以應對疾病爆發並提升食品安全。區域製造能力和不斷成長的區域試劑供應鏈也在逐步建立，以減輕跨境貿易中斷的影響，並支援大規模檢測的快速反應。這些區域差異凸顯了根據區域的具體臨床需求、基礎設施成熟度和政策重點，客製化產品系列、監管策略和分銷模式的重要性。

評估儀器供應商、試劑製造商、檢測開發商以及軟體和服務供應商的競爭動態和夥伴關係差異化

獸醫分子診斷領域的競爭格局呈現出多元化的態勢，既有成熟的平台供應商，也有專注於特定應用和現場部署技術的靈活新興企業。儀器製造商持續投資於開放平台相容性，以確保耗材和服務收入來源；試劑供應商則著重提供檢驗的套件和品管材料，以促進實驗室資格認證和日常應用。同時，軟體供應商和服務供應商透過分析演算法、解讀演算法以及雲端報告來減輕終端用戶實驗室和臨床醫生的負擔，從而實現差異化競爭。

檢測開發商與設備供應商之間的共同開發契約能夠加快驗證週期，並促成對診斷中心和參考實驗室更具吸引力的捆綁式產品。與學術和研究機構的合作通常能夠支持檢測設計和生物資訊流程的創新，從而產生早期驗證數據，降低商業性上市的風險。專注於照護現場和可攜式定序的新興企業憑藉其在水產養殖、畜牧業現場監測和野生動物監測領域分散檢測的潛力而日益受到關注，促使現有企業採取戰略應對措施，以增強產品平臺。

最後，透過品質、合規性和客戶支援實現差異化變得越來越重要。買家優先考慮能夠提供全面培訓、完善的品質控制材料和快速服務回應以最大限度減少停機時間的合作夥伴。投資於生命週期服務、遠端故障排除和以證據支持的性能聲明的公司，更有可能與診斷中心和獸醫醫院網路簽訂長期合約。在這種競爭激烈的環境中，能夠獲得最持久價值的公司將依賴周密的聯盟構建、清晰的檢驗路徑以及對最終用戶體驗的關注。

為產業領導者提供優先且切實可行的策略，以增強韌性、加速臨床應用並擴大診斷在動物健康領域的影響力。

產業領導者應採取一系列切實可行的優先行動，以增強獸醫分子診斷的韌性，加速其應用，並提升其臨床影響力。首先，在設計產品系列，應充分考慮互通性，透過在多種儀器平台上檢驗檢測方法，並確保其與廣泛使用的資料管理系統相容來實現。其次，應投資區域性生產和戰略供應商協議，以確保關鍵試劑和酵素的供應，同時實施庫存最佳化策略，以應對短期貿易中斷的影響。

第三，我們將透過針對重點疾病組合和物種特異性適應症產生可靠的效能數據，使我們的監管和臨床檢驗策略與目標終端使用者的需求保持一致。我們將儘早與參考實驗室和學術合作夥伴合作，共同開發證據包，以加速診斷中心和臨床機構的採用。第四，我們將透過捆綁軟體、解讀分析和培訓計畫來增強我們的服務，從而降低獸醫醫院和診所採用分子診斷的運作門檻。第五，我們將採用模組化的市場推廣模式，將高通量參考實驗室解決方案與適用於水產養殖、畜牧業和野生動物監測的小型化、現場即用型平台結合。

最後，在設計雲端基礎的報告系統時，應優先考慮資料管治、網路安全和互通性標準，並維持關於驗證、品管和供應鏈溯源的透明溝通。透過實施這些有針對性的措施，企業可以減少商業摩擦，支持循證應用，並與實驗室和臨床網路建立長期夥伴關係，從而加速分子診斷在獸醫醫療保健領域的廣泛應用。

描述一種嚴謹的混合方法研究途徑，該方法整合了第一手訪談、技術文獻和供應鏈基準，以檢驗研究結果。

本研究整合了定性和定量方法，旨在對獸醫分子診斷領域進行穩健且基於實證的理解。調查方法首先對同行評審文獻、監管指南、技術白皮書和行業出版物進行了全面回顧，以確定基準定義、技術能力和檢驗標準。在此基準上，主要研究包括對實驗室主任、獸醫臨床醫生、檢測開發人員、儀器工程師和採購專家進行結構化訪談，以深入了解工作流程、應用障礙和採購行為等方面的實際問題。

此外，我們對產品和技術細分進行了系統性梳理，以使耗材類別、設備類型和軟體產品與特定物種和疾病的用例相匹配。我們將一手資訊與二手資訊和專家回饋進行比較，並進行了交叉檢驗，以消除差異並確保內部一致性。分析方法包括：對定性輸入進行主題綜合分析；對工作流程和用例進行基準基準化分析，以評估操作適用性；以及對供應鏈進行分析，以識別風險節點和緩解策略。

需要指出的是，本研究存在一些限制。不斷變化的貿易政策、快速的平台創新以及局部監管政策的調整都可能在資料收集後改變市場動態，因此相關人員應將研究結果視為決策支援框架，而非靜態預測。為確保透明度，我們記錄了調查方法、資料來源、受訪者概況以及檢驗步驟，以便讀者評估具體研究結果在其自身情境中的適用性。這種混合方法為獸醫分子診斷領域的策略決策、產品規劃和監管推廣提供了基礎。

總結全文，重點在於技術創新、營運韌性和協作夥伴關係關係對於實現持續診斷影響的重要性。

獸醫分子診斷的發展軌跡呈現出技術日益複雜、數據主導服務整合度不斷提高以及採購和監管環境不斷演變的特點，這些因素共同為相關人員帶來了機會和挑戰。目前，各方正朝著兼顧分析績效和營運可行性的解決方案邁進，力求無論採用何種技術或動物類型，都能為臨床照護、監測和研究提供更快、更準確的結果。同時，供應鏈的脆弱性和關稅相關的壓力要求制定策略規劃，以確保檢測的連續性，並在不同的終端用戶環境中維持服務水準。

因此，投資於互通平台、多元化供應鏈和循證檢驗的機構將更有利於支持分子診斷在獸醫學領域日益擴展的作用。同樣重要的是，他們致力於終端使用者培訓、品質保證和資料管理，從而將分析結果轉化為改善動物健康狀況的成效。永續發展取決於將技術創新與務實的部署策略、強大的夥伴關係以及適應性採購慣例相結合，從而在獸醫學領域實現可擴展的高品質診斷服務。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 將次世代定序應用於獸醫診斷中的病原體快速檢測
  • 擴大照護現場PCR檢測在牲畜和伴侶動物現場疾病篩檢的應用
  • 在動物健康監測中採用數位PCR技術進行病毒量定量
  • 利用CRISPR的診斷工具進行通用感染疾病的超靈敏檢測
  • 開發用於同時檢測多種獸醫病原體的多重分子檢測板
  • 運用人工智慧驅動的數據分析來增強對分子診斷結果的解讀
  • 推出一種用於獸醫快速分子檢測的可攜式等溫擴增裝置
  • 利用分子檢測技術發展遠距離診斷服務，促進分散式獸醫護理
  • 引入分子生物標記用於動物病原體抗菌素抗藥性的早期檢測
  • 獸醫診斷實驗室與生物技術公司之間的合作加速了檢測方法的開發和檢驗。

第6章美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：按產品分類的動物分子診斷市場

  • 耗材和試劑
    • 酵素
    • 套件
    • 探針和引子
  • 裝置
    • PCR設備
    • 序列器
  • 軟體和服務

第9章 依技術分類的動物分子診斷市場

  • 常規PCR
  • 數位PCR
  • 等溫擴增
  • 微陣列
  • 次世代定序
    • Illumina定序
    • 離子流定序
    • 牛津奈米孔
  • 即時PCR

第10章 依動物類型分類的動物分子診斷市場

  • 水產養殖
    • 魚
    • 貝類
  • 鳥類
  • 伴侶動物
    • 貓
    • 狗
  • 家畜
    • 牛
    • 家禽
    • 豬
  • 野生動物

第11章：依疾病類型分類的動物分子診斷市場

  • 遺傳性疾病
  • 感染疾病
    • 細菌感染疾病
    • 黴菌感染疾病
    • 寄生蟲感染疾病
    • 病毒感染
  • 腫瘤學

第12章：依最終使用者分類的動物分子診斷市場

  • 學術機構
  • 診斷中心
  • 參考實驗室
  • 研究機構
  • 獸醫醫院和診所

第13章：按地區分類的獸醫分子診斷市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 動物分子診斷市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國動物分子診斷市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • IDEXX Laboratories, Inc.
    • Thermo Fisher Scientific Inc.
    • Zoetis Inc.
    • QIAGEN NV
    • Bio-Rad Laboratories, Inc.
    • Neogen Corporation
    • Heska Corporation
    • Ceva Sante Animale SA
    • Vetoquinol SA
    • Eurofins Scientific SE
Product Code: MRR-034B50030397

The Veterinary Molecular Diagnostic Market is projected to grow by USD 1,301.76 million at a CAGR of 9.44% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 632.40 million
Estimated Year [2025] USD 692.27 million
Forecast Year [2032] USD 1,301.76 million
CAGR (%) 9.44%

Establishing context for decision-makers amid rapid technological advances and evolving operational challenges in veterinary molecular diagnostics

The veterinary molecular diagnostics field stands at the confluence of rapid technological innovation and intensifying demand for precise, timely testing across animal health sectors. Recent advances in polymerase chain reaction modalities, digital and isothermal amplification techniques, microarray platforms, and high-throughput sequencing have broadened the possibilities for detecting infectious agents, characterizing genetic disorders, and supporting oncology in veterinary practice. Concurrently, an expanding base of end users-from academic institutions and research centers to diagnostic laboratories and clinical veterinary hospitals-has generated a more complex ecosystem where diagnostics must be robust, cost-effective, and integrated with clinical workflows.

As diagnostic capabilities evolve, stakeholders face a shifting landscape of regulatory requirements, supply chain sensitivities, and cross-sector collaborations. Instruments and consumables that once flowed predictably through established distributors are now influenced by global trade dynamics and supplier consolidation, while software and interpretive services are assuming greater importance to translate raw data into actionable clinical decisions. This introduction frames the subsequent analysis by emphasizing the need for strategic alignment between technology selection, operational capacity, and market-facing services. By situating the reader within this dynamic environment, the narrative that follows unpacks transformative trends, regulatory pressures, segmentation-driven opportunities, and recommended actions to navigate near-term disruptions and accelerate adoption across diverse animal types and care settings.

Overall, this section establishes context for decision-makers and researchers to assess risk, prioritize investments, and design interventions that leverage molecular diagnostics to improve animal health outcomes while managing operational complexity.

Examining the pivotal technological, regulatory, and operational shifts reshaping how veterinary molecular diagnostics are developed, validated, and delivered

The landscape of veterinary molecular diagnostics is undergoing transformative shifts driven by technological convergence, changing clinical expectations, and systemic pressures on supply chains and reimbursement models. Next-generation sequencing has transitioned from niche research use into more routine applications for pathogen discovery and antimicrobial resistance profiling, while real-time PCR and digital PCR remain workhorses for targeted, high-sensitivity detection. Simultaneously, isothermal amplification techniques and portable platforms are enabling point-of-care and field diagnostics for aquaculture, livestock, and wildlife surveillance, which supports faster outbreak response and herd-level decision-making. These changes are reinforced by software advances in bioinformatics and cloud-based interpretation that reduce turnaround times and democratize access to complex analyses.

Market dynamics are also being reshaped by consolidation among reagent suppliers and instrumentation providers, heightened regulatory scrutiny of diagnostic validation and data integrity, and growing pressure from end users for bundled solutions that combine assays, instruments, and interpretive services. In addition, the rising complexity of multi-species testing panels and the need for cross-platform compatibility has placed a premium on open architecture instruments and validated consumables. As a result, partnerships between assay developers, platform providers, and research institutions are becoming a strategic imperative to accelerate time-to-market and ensure clinical utility.

In short, the field is shifting from isolated technology deployments toward integrated, service-oriented models that emphasize data-driven diagnostics, operational resilience, and scalable workflows. Stakeholders that anticipate these shifts and align product development, distribution strategies, and customer support accordingly will gain competitive advantage in an increasingly sophisticated and outcome-focused veterinary healthcare market.

Analyzing the multifaceted operational and procurement consequences of United States tariff measures in 2025 on veterinary molecular diagnostics supply chains

Cumulative tariff developments originating in the United States for 2025 have introduced multifaceted impacts on the veterinary molecular diagnostics supply chain, procurement strategies, and cost structures. Tariff-induced increases on imported instruments and certain reagents have pressured laboratory procurement budgets and influenced decisions about where to source high-value capital equipment versus single-use consumables. As a consequence, some laboratories and veterinary networks have accelerated localization strategies, seeking domestic distributors or regional manufacturing partners to reduce exposure to trade friction and avoid inventory volatility.

These trade measures have also prompted buyers to reassess total cost of ownership for PCR instruments, sequencers, and ancillary automation, factoring in longer lead times, recalibrated maintenance agreements, and the potential for increased spare parts costs. For reagent-intensive workflows, tariffs on raw materials and specialty enzymes have elevated attention on supply diversification, inventory hedging, and longer contract terms with suppliers who can guarantee continuity. In parallel, software and interpretive services, which are less dependent on cross-border physical shipments, have emerged as lower-tariff avenues to add value to diagnostic offerings and to offset hardware-related cost pressures.

Regulatory and procurement teams have responded by renegotiating supplier agreements, exploring strategic partnerships with regional manufacturers, and prioritizing open-platform instruments that accept a range of validated consumables to mitigate single-supplier risk. At the same time, laboratories have increased investments in workflow efficiency and multiplexing assays to reduce per-test reagent consumption. Collectively, these responses are reshaping purchasing patterns, driving more collaborative supplier relationships, and accelerating adoption of resilient procurement practices that balance cost, performance, and supply chain security under a more protectionist trade environment.

Unpacking detailed segmentation across product, technology, animal type, disease focus, and end-user settings to guide targeted diagnostic strategies and development

A nuanced understanding of market segmentation reveals where demand originates, how technology choices intersect with animal species and disease priorities, and which end-user settings will drive sustained adoption. Based on product distinctions, the market comprises consumables and reagents, instruments, and software and services. Consumables and reagents can be understood through their enzyme formulations, assay kits, and probes and primers that are critical for assay sensitivity and specificity, while instrument categories range from PCR instruments to sequencers that serve different throughput and application needs. Software and services increasingly function as the connective tissue that enables data interpretation, workflow orchestration, and remote diagnostics.

When viewed through the lens of technology, conventional PCR, digital PCR, isothermal amplification, microarray, next-generation sequencing, and real-time PCR present differentiated value propositions. Next-generation sequencing itself spans Illumina sequencing, Ion Torrent sequencing, and Oxford Nanopore approaches, each offering distinct trade-offs in read length, throughput, and field deployability. These technology choices map closely to animal type considerations where aquaculture testing for fish and shellfish requires robust, often field-capable assays; avian applications prioritize rapid pathogen detection to protect flock health; companion animal diagnostics, particularly for cats and dogs, emphasize genetic disorder screening and oncology panels; livestock testing for cattle, poultry, and swine centers on herd-level surveillance and production-impacting infectious diseases; and wildlife testing calls for broad-spectrum pathogen discovery and conservation-focused genetic analysis.

Disease-type segmentation further refines validation and development priorities, with genetic disorders necessitating high-fidelity genotyping assays, infectious diseases demanding sensitive and rapid pathogen detection across bacterial, fungal, parasitic, and viral etiologies, and oncology requiring assays that can profile tumor-associated variants. Finally, end users-academic institutes, diagnostic centers, reference laboratories, research institutes, and veterinary hospitals and clinics-differ in throughput, regulatory expectations, and willingness to adopt complex workflows. Academic and research settings often pilot innovative technologies and bioinformatics methods, reference laboratories prioritize standardized, high-throughput assays with rigorous QC, while clinical veterinary hospitals seek integrated solutions that deliver rapid, interpretable results to inform patient care. Taken together, these segmentation dimensions provide a roadmap for product development, validation strategies, and go-to-market prioritization that align technological capabilities with the operational needs of each user cohort.

Mapping regional demand drivers, infrastructure maturity, and regulatory diversity across the Americas, Europe Middle East Africa, and Asia-Pacific to inform deployment strategies

Regional dynamics play a decisive role in shaping demand, regulatory approaches, and deployment models for veterinary molecular diagnostics. In the Americas, a mature veterinary services market, robust research infrastructure, and advanced livestock and companion animal care ecosystems drive demand for high-throughput platforms, specialized reagents, and integrated software solutions that support both clinical decision-making and epidemiological surveillance. The region's strong base of private veterinary practices and reference labs also supports early adoption of novel assays and companion diagnostics tailored to companion animals and production species.

Across Europe, the Middle East and Africa, a diversity of regulatory environments and varying levels of laboratory capacity produce a heterogeneous adoption pattern. Western and northern European markets tend to adopt high-complexity technologies with stringent validation standards, while parts of the Middle East and Africa emphasize cost-effective, field-ready diagnostics to manage transboundary animal diseases and zoonotic risks. Capacity building and public-private partnerships are accelerating molecular diagnostic deployment in several subregions, supported by collaborative initiatives that strengthen laboratory networks and data-sharing frameworks.

The Asia-Pacific region is characterized by rapidly expanding veterinary services, sizable aquaculture industries, and intensive livestock production systems that heighten demand for scalable diagnostics and surveillance tools. Countries in this region are investing in sequencing and multiplex assay capabilities to manage disease outbreaks and to enhance food safety. Regional manufacturing capability and growing local reagent supply chains are also emerging, which helps mitigate the effects of cross-border trade disruptions and supports faster turnaround times for high-volume testing needs. These regional contrasts underscore the importance of tailoring product portfolios, regulatory strategies, and distribution models to localized clinical needs, infrastructure maturity, and policy priorities.

Assessing competitive dynamics and partnership-driven differentiation among instrument providers, reagent manufacturers, assay developers, and software service vendors

Competitive dynamics in veterinary molecular diagnostics reflect a mix of established platform providers, specialized assay developers, and agile startups that focus on niche applications or field-deployable technologies. Instrument manufacturers continue to invest in open-platform compatibility to capture consumable and service revenue streams, while reagent suppliers emphasize validated kits and quality control materials that accelerate laboratory accreditation and routine use. At the same time, software vendors and service providers are differentiating through analytics, interpretive algorithms, and cloud-enabled reporting that reduce the burden on end-user laboratories and clinicians.

Collaboration remains an important strategy: co-development agreements between assay developers and instrument providers accelerate validation cycles and enable bundled offerings that appeal to diagnostic centers and reference laboratories. Partnerships with academic institutions and research institutes often underpin innovation in assay design and bioinformatics pipelines, producing early-stage validation data that de-risks commercial launches. Startups focusing on point-of-care and portable sequencing are attracting attention for their potential to decentralize testing in aquaculture, livestock field surveillance, and wildlife monitoring, prompting strategic responses from incumbents seeking to fortify their product pipelines.

Finally, differentiation through quality, regulatory compliance, and customer support is increasingly significant. Buyers prioritize partners who can provide comprehensive training, robust QC materials, and rapid service response to minimize downtime. Companies that invest in lifecycle services, remote troubleshooting, and evidence-backed performance claims are better positioned to secure long-term contracts with diagnostic centers and veterinary hospital networks. In this competitive landscape, thoughtful alliance-building, clear validation pathways, and a focus on end-user experience determine which organizations capture the most durable value.

Prioritized, practical strategies for industry leaders to enhance resilience, accelerate clinical adoption, and expand diagnostic impact across animal health sectors

Industry leaders should pursue a set of practical, prioritized actions to strengthen resilience, accelerate adoption, and support clinical impact in veterinary molecular diagnostics. First, design product portfolios with interoperability in mind by validating assays across multiple instrument platforms and ensuring compatibility with widely used data management systems; this reduces procurement friction and expands addressable markets. Second, invest in regional manufacturing and strategic supplier agreements to secure critical reagents and enzymes, while implementing inventory optimization techniques to buffer short-term trade disruptions.

Third, align regulatory and clinical validation strategies to the needs of target end users by generating robust performance data for prioritized disease panels and species-specific indications. Engage early with reference laboratories and academic partners to co-develop evidence packages that facilitate adoption in diagnostic centers and clinical settings. Fourth, enhance service offerings by bundling software, interpretive analytics, and training programs that lower the operational barriers for veterinary hospitals and clinics adopting molecular diagnostics. Fifth, adopt modular go-to-market models that pair high-throughput reference lab solutions with scaled-down, field-capable platforms for aquaculture, livestock, and wildlife surveillance.

Finally, prioritize data governance, cybersecurity, and interoperability standards when designing cloud-based reporting systems, and maintain transparent communication about validation, quality control, and supply chain provenance. By executing these targeted actions, companies can reduce commercial friction, support evidence-based adoption, and create durable partnerships with laboratories and clinical networks that accelerate the uptake of molecular diagnostics across animal health domains.

Describing a rigorous mixed-methods research approach that synthesizes primary interviews, technical literature, and supply chain benchmarking to validate insights

This research integrates qualitative and quantitative methods to ensure a robust, evidence-based understanding of the veterinary molecular diagnostics landscape. The methodological approach began with a comprehensive review of peer-reviewed literature, regulatory guidance, technical white papers, and industry publications to establish baseline definitions, technology capabilities, and validation criteria. Building on this foundation, primary research included structured interviews with laboratory directors, veterinary clinicians, assay developers, instrument engineers, and procurement specialists to capture practical insights on workflow, adoption barriers, and purchasing behavior.

Additionally, a systematic mapping of product and technology segmentation was performed to align consumable categories, instrument classes, and software offerings with species-specific and disease-focused use cases. Cross-validation exercises compared primary insights with secondary sources and subject matter expert feedback to reconcile divergent perspectives and ensure internal consistency. Analytical techniques included thematic synthesis for qualitative inputs, workflow and use-case benchmarking to assess operational fit, and supply chain analysis to identify risk nodes and mitigation strategies.

Limitations are acknowledged: evolving trade policy, rapid platform innovations, and localized regulatory shifts can change dynamics after data collection, so stakeholders should treat findings as a decision-support framework rather than a static prediction. To support transparency, the methodology documents sources of primary data, interviewee profiles, and validation steps to allow readers to assess the applicability of specific findings to their contexts. This mixed-methods approach provides a defensible basis for strategic decisions, product planning, and regulatory engagement in the veterinary molecular diagnostics domain.

Concluding synthesis that emphasizes aligning technological innovation, operational resilience, and collaborative partnerships to realize durable diagnostic impact

The trajectory of veterinary molecular diagnostics is characterized by growing technical sophistication, heightened integration of data-driven services, and evolving procurement and regulatory landscapes that together create both opportunities and responsibilities for stakeholders. Across technologies and animal types, there is a clear movement toward solutions that balance analytical performance with operational feasibility, enabling faster, more accurate outcomes for clinical care, surveillance, and research. At the same time, supply chain vulnerabilities and tariff-related pressures necessitate strategic planning to ensure continuity of testing and maintain service levels across diverse end-user environments.

Consequently, organizations that invest in interoperable platforms, diversified supply chains, and evidence-led validation will be best positioned to support the expanding role of molecular diagnostics in veterinary medicine. Equally important is the commitment to end-user training, quality assurance, and data stewardship to translate analytical gains into improved animal health outcomes. The conclusion synthesizes the core message: sustainable progress depends on aligning technological innovation with pragmatic deployment strategies, robust partnerships, and adaptive procurement practices that together enable scalable, high-quality diagnostic services across the full spectrum of veterinary care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of next-generation sequencing for rapid pathogen detection in veterinary diagnostics
  • 5.2. Expansion of point-of-care PCR assays for on-site disease screening in livestock and companion animals
  • 5.3. Adoption of digital PCR technologies to quantify viral load in animal health monitoring
  • 5.4. Use of CRISPR-based diagnostic tools for ultrasensitive detection of zoonotic pathogens
  • 5.5. Development of multiplex molecular panels for simultaneous detection of multiple veterinary pathogens
  • 5.6. Incorporation of AI-driven data analytics to enhance interpretation of molecular diagnostic results
  • 5.7. Emergence of portable isothermal amplification devices for field-ready molecular testing in veterinary settings
  • 5.8. Growth of tele-diagnostics services leveraging molecular assays for decentralized veterinary care
  • 5.9. Implementation of molecular biomarkers for early detection of antimicrobial resistance in animal pathogens
  • 5.10. Collaboration between veterinary diagnostic laboratories and biotech firms to accelerate assay development and validation

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Veterinary Molecular Diagnostic Market, by Product

  • 8.1. Consumables & Reagents
    • 8.1.1. Enzymes
    • 8.1.2. Kits
    • 8.1.3. Probes & Primers
  • 8.2. Instruments
    • 8.2.1. PCR Instruments
    • 8.2.2. Sequencers
  • 8.3. Software & Services

9. Veterinary Molecular Diagnostic Market, by Technology

  • 9.1. Conventional PCR
  • 9.2. Digital PCR
  • 9.3. Isothermal Amplification
  • 9.4. Microarray
  • 9.5. Next-Generation Sequencing
    • 9.5.1. Illumina Sequencing
    • 9.5.2. Ion Torrent Sequencing
    • 9.5.3. Oxford Nanopore
  • 9.6. Real-Time PCR

10. Veterinary Molecular Diagnostic Market, by Animal Type

  • 10.1. Aquaculture
    • 10.1.1. Fish
    • 10.1.2. Shellfish
  • 10.2. Avian
  • 10.3. Companion Animals
    • 10.3.1. Cats
    • 10.3.2. Dogs
  • 10.4. Livestock
    • 10.4.1. Cattle
    • 10.4.2. Poultry
    • 10.4.3. Swine
  • 10.5. Wildlife

11. Veterinary Molecular Diagnostic Market, by Disease Type

  • 11.1. Genetic Disorders
  • 11.2. Infectious Diseases
    • 11.2.1. Bacterial Infections
    • 11.2.2. Fungal Infections
    • 11.2.3. Parasitic Infections
    • 11.2.4. Viral Infections
  • 11.3. Oncology

12. Veterinary Molecular Diagnostic Market, by End User

  • 12.1. Academic Institutes
  • 12.2. Diagnostic Centers
  • 12.3. Reference Laboratories
  • 12.4. Research Institutes
  • 12.5. Veterinary Hospitals & Clinics

13. Veterinary Molecular Diagnostic Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Veterinary Molecular Diagnostic Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Veterinary Molecular Diagnostic Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. IDEXX Laboratories, Inc.
    • 16.3.2. Thermo Fisher Scientific Inc.
    • 16.3.3. Zoetis Inc.
    • 16.3.4. QIAGEN N.V.
    • 16.3.5. Bio-Rad Laboratories, Inc.
    • 16.3.6. Neogen Corporation
    • 16.3.7. Heska Corporation
    • 16.3.8. Ceva Sante Animale S.A.
    • 16.3.9. Vetoquinol S.A.
    • 16.3.10. Eurofins Scientific SE

LIST OF FIGURES

  • FIGURE 1. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. VETERINARY MOLECULAR DIAGNOSTIC MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. VETERINARY MOLECULAR DIAGNOSTIC MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. VETERINARY MOLECULAR DIAGNOSTIC MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY CONSUMABLES & REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY CONSUMABLES & REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY CONSUMABLES & REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY CONSUMABLES & REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY CONSUMABLES & REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY CONSUMABLES & REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY CONSUMABLES & REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ENZYMES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ENZYMES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ENZYMES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ENZYMES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ENZYMES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ENZYMES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY PROBES & PRIMERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY PROBES & PRIMERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY PROBES & PRIMERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY PROBES & PRIMERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY PROBES & PRIMERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY PROBES & PRIMERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY PCR INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY PCR INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY PCR INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY PCR INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY PCR INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY PCR INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY SEQUENCERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY SEQUENCERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY SEQUENCERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY SEQUENCERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY SEQUENCERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY SEQUENCERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY CONVENTIONAL PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY CONVENTIONAL PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY CONVENTIONAL PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY CONVENTIONAL PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY CONVENTIONAL PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY CONVENTIONAL PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY DIGITAL PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY MICROARRAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY MICROARRAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY MICROARRAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ILLUMINA SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ILLUMINA SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ILLUMINA SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ILLUMINA SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ILLUMINA SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ILLUMINA SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ION TORRENT SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ION TORRENT SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ION TORRENT SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ION TORRENT SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ION TORRENT SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ION TORRENT SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY OXFORD NANOPORE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY OXFORD NANOPORE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY OXFORD NANOPORE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY OXFORD NANOPORE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY OXFORD NANOPORE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY OXFORD NANOPORE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY REAL-TIME PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY REAL-TIME PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY REAL-TIME PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY REAL-TIME PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY REAL-TIME PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY REAL-TIME PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY AQUACULTURE, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY AQUACULTURE, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY AQUACULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY AQUACULTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY AQUACULTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY AQUACULTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY AQUACULTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY AQUACULTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY FISH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY FISH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY FISH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY FISH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY FISH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY FISH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY SHELLFISH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY SHELLFISH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY SHELLFISH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY SHELLFISH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY SHELLFISH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY SHELLFISH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY AVIAN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY AVIAN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY AVIAN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY AVIAN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY AVIAN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY AVIAN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY COMPANION ANIMALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY COMPANION ANIMALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY COMPANION ANIMALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY COMPANION ANIMALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY CATS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY CATS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY CATS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY CATS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY CATS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY CATS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY DOGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY DOGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY DOGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY DOGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY DOGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY DOGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY LIVESTOCK, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY LIVESTOCK, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY LIVESTOCK, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY LIVESTOCK, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY LIVESTOCK, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY LIVESTOCK, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY LIVESTOCK, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY LIVESTOCK, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY CATTLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY CATTLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY CATTLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY CATTLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY CATTLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY CATTLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY POULTRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY POULTRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY POULTRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY POULTRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY POULTRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY POULTRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY SWINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY SWINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY SWINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY SWINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY SWINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY SWINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY WILDLIFE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY WILDLIFE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY WILDLIFE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY WILDLIFE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY WILDLIFE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY WILDLIFE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY GENETIC DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY GENETIC DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY GENETIC DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY GENETIC DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ACADEMIC INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ACADEMIC INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ACADEMIC INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ACADEMIC INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ACADEMIC INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY ACADEMIC INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY VETERINARY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY VETERINARY HOSPITALS & CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY VETERINARY HOSPITALS & CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY VETERINARY HOSPITALS & CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY VETERINARY HOSPITALS & CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY VETERINARY HOSPITALS & CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 277. AMERICAS VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 278. AMERICAS VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 279. AMERICAS VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 280. AMERICAS VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 281. AMERICAS VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 282. AMERICAS VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY CONSUMABLES & REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 283. AMERICAS VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 284. AMERICAS VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 285. AMERICAS VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 286. AMERICAS VETERINARY MOLECULAR DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION